Literature DB >> 20800404

Choline PET/CT for prostate cancer: main clinical applications.

Chiara Fuccio1, Domenico Rubello, Paolo Castellucci, Maria Cristina Marzola, Stefano Fanti.   

Abstract

Several studies investigated the potential roles of imaging modalities in prostate cancer patients for the evaluation of intra-prostatic disease, stage and restage. However no precise guidelines exist about the use of imaging modalities, in particular about the role of PET/CT hybrid imaging. Considering the results of the literature and our experience, we tried to summarize the main applications of choline positron emission tomography (PET) in prostate cancer patients. The use of choline PET/CT for initial diagnosis and staging is not recommended as a first-line method. Instead the main and important application of choline PET/CT is represented by the restaging of the disease in case of biochemical relapse for the detection of lymph node and distant recurrence. In particular choline PET/CT could play a crucial role as first diagnostic procedure in prostate cancer patients who show a fast growing Prostate Specific Antigen (PSA) kinetics.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20800404     DOI: 10.1016/j.ejrad.2010.07.023

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  19 in total

Review 1.  Non-FDG PET in oncology.

Authors:  R Núñez Miller; M A Pozo
Journal:  Clin Transl Oncol       Date:  2011-11       Impact factor: 3.405

Review 2.  Individualized image-based lymph node irradiation for prostate cancer.

Authors:  Hanneke J M Meijer; Oscar A Debats; Emile N J Th van Lin; Marco van Vulpen; J Alfred Witjes; Wim J G Oyen; Jelle O Barentsz; Johannes H A M Kaanders
Journal:  Nat Rev Urol       Date:  2013-05-28       Impact factor: 14.432

3.  Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study.

Authors:  Chiara Fuccio; Riccardo Schiavina; Paolo Castellucci; Domenico Rubello; Giuseppe Martorana; Monica Celli; Claudio Malizia; Marta Barios Profitos; Maria Cristina Marzola; Vincenzina Pettinato; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-07-06       Impact factor: 9.236

4.  Usefulness of MRI-assisted metabolic volumetric parameters provided by simultaneous (18)F-fluorocholine PET/MRI for primary prostate cancer characterization.

Authors:  Yong-Il Kim; Gi Jeong Cheon; Jin Chul Paeng; Jeong Yeon Cho; Cheol Kwak; Keon Wook Kang; June-Key Chung; Euishin Edmund Kim; Dong Soo Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-03-11       Impact factor: 9.236

5.  Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial.

Authors:  Francesco Ceci; Ken Herrmann; Paolo Castellucci; Tiziano Graziani; Christina Bluemel; Riccardo Schiavina; Christian Vollmer; Sabine Droll; Eugenio Brunocilla; Renzo Mazzarotto; Andreas K Buck; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-08-15       Impact factor: 9.236

6.  PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.

Authors:  Steven P Rowe; Katarzyna J Macura; Esther Mena; Amanda L Blackford; Rosa Nadal; Emmanuel S Antonarakis; Mario Eisenberger; Michael Carducci; Hong Fan; Robert F Dannals; Ying Chen; Ronnie C Mease; Zsolt Szabo; Martin G Pomper; Steve Y Cho
Journal:  Mol Imaging Biol       Date:  2016-06       Impact factor: 3.488

Review 7.  Molecular imaging of urogenital diseases.

Authors:  Steve Y Cho; Zsolt Szabo
Journal:  Semin Nucl Med       Date:  2014-03       Impact factor: 4.446

8.  Comparison of Prostate-Specific Membrane Antigen-Based 18F-DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer.

Authors:  Steven P Rowe; Katarzyna J Macura; Anthony Ciarallo; Esther Mena; Amanda Blackford; Rosa Nadal; Emmanuel S Antonarakis; Mario A Eisenberger; Michael A Carducci; Ashley E Ross; Philip W Kantoff; Daniel P Holt; Robert F Dannals; Ronnie C Mease; Martin G Pomper; Steve Y Cho
Journal:  J Nucl Med       Date:  2015-10-22       Impact factor: 10.057

9.  Prostate cancer recurrence after radical prostatectomy: the role of 3-T diffusion imaging in multi-parametric magnetic resonance imaging.

Authors:  Valeria Panebianco; Flavio Barchetti; Alessandro Sciarra; Daniela Musio; Valerio Forte; Vincenzo Gentile; Vincenzo Tombolini; Carlo Catalano
Journal:  Eur Radiol       Date:  2013-02-02       Impact factor: 5.315

10.  11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT.

Authors:  Francesco Ceci; Paolo Castellucci; Tiziano Graziani; Riccardo Schiavina; Eugenio Brunocilla; Renzo Mazzarotto; Maria Ntreta; Filippo Lodi; Giuseppe Martorana; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-12-18       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.